 To confirm the safety of BIBF 1120 at a dose level up to 200 mg x 2day i.e., overseas recommended Phase III dose for combination treatment with standard therapy of docetaxel 60 mgm2 and 75 mgm2 in Japanese advanced non small cell lung cancer NSCLC patients with stage IIIBIV or recurrent after failure of first line chemotherapy and to determine the recommended dose for the Phase II trial. 